RGT · ASX

Argent Biopharma Ltd (ASX:RGT)

AU$0.08

 -0.005 (-5.882%)
ASX:Live
11/07/2025 11:03:11 AM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

RGT Overview

RGT Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About RGT

Website

Argent Biopharma Ltd

Telephone

61.8.6382.3390

Address

Suite 1 295 Rokeby Road Subiaco, Western Australia (WA) 6008

Description

Argent BioPharma Ltd. engages in the production of medical marijuana. Its Endocannabinoid system covers all cells and nerves; it is the messenger of information flowing between immune system and the central nervous system. The company was founded by Roby Zomer on October 21, 2005 and is headquartered in Perth, Australia.

RGT Price Chart

Key Stats

Market Cap

AU$5.25M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.07 - 0.57

Trade Value (12mth)

AU$2,474.00

1 week

6.25%

1 month

-4.49%

YTD

-50%

1 year

-72.13%

All time high

4950.00

Key Fundamentals

EPS 3 yr Growth

-94.30%

EBITDA Margin

%

Operating Cashflow

-$15m

Free Cash Flow Return

0.00%

ROIC

0.00%

Interest Coverage

-35.00

Quick Ratio

0.20

Other Data

Shares on Issue (Fully Dilluted)

51m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

RGT Announcements

Latest Announcements

Date Announcements

08 July 25

EU-GMP Cannabinoid API Supplied for Epilepsy in Slovenia

×

EU-GMP Cannabinoid API Supplied for Epilepsy in Slovenia

02 July 25

Notification regarding unquoted securities - RGT

×

Notification regarding unquoted securities - RGT

01 July 25

Notification of cessation of securities - RGT

×

Notification of cessation of securities - RGT

10 June 25

Company Presentation

×

Company Presentation

02 May 25

Notification of cessation of securities - RGT

×

Notification of cessation of securities - RGT

30 April 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

24 April 25

s708A Cleansing Notice

×

s708A Cleansing Notice

24 April 25

Application for quotation of securities - RGT

×

Application for quotation of securities - RGT

24 April 25

Cancel - Application for quotation of securities - RGT

×

Cancel - Application for quotation of securities - RGT

23 April 25

Application for quotation of securities - RGT

×

Application for quotation of securities - RGT

23 April 25

Refinancing of Convertible Security Agreement

×

Refinancing of Convertible Security Agreement

23 April 25

Notification regarding unquoted securities - RGT

×

Notification regarding unquoted securities - RGT

23 April 25

Notification regarding unquoted securities - RGT

×

Notification regarding unquoted securities - RGT

23 April 25

Application for quotation of securities - RGT

×

Application for quotation of securities - RGT

23 April 25

Application for quotation of securities - RGT

×

Application for quotation of securities - RGT

23 April 25

Application for quotation of securities - RGT

×

Application for quotation of securities - RGT

23 April 25

s708A Cleansing Notice

×

s708A Cleansing Notice

17 April 25

Operational and Clinical Development Update

×

Operational and Clinical Development Update

15 April 25

Strategic Agreement to Enhance Cannabinoid Development

×

Strategic Agreement to Enhance Cannabinoid Development

11 April 25

Results of Meeting

×

Results of Meeting

09 April 25

Strategic Collaboration Agreement for Malta Facility

×

Strategic Collaboration Agreement for Malta Facility

03 April 25

CannEpil Receives Approval for Prescription in Germany

×

CannEpil Receives Approval for Prescription in Germany

17 March 25

CimetrA Phase IIb Clinical Trial Results

×

CimetrA Phase IIb Clinical Trial Results

12 March 25

Exclusive Agreement for Malta Manufacturing Facility

×

Exclusive Agreement for Malta Manufacturing Facility

10 March 25

Notice of General Meeting/Proxy Form

×

Notice of General Meeting/Proxy Form

RGT Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -7.93 -7.07 -0.47 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -7.93 -7.07 -0.47 Lock Lock Lock
     Growth % Lock Lock Lock Lock 4.8 10.8 93.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -5.18 -4.19 -0.29 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -5.79 -4.13 -0.40 Lock Lock Lock
     Growth % Lock Lock Lock Lock -41.6 18.9 93.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock -36.2 -82.6 -133.3 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 2.14 -2.21 -0.11 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.99 -2.21 -0.11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -66.3 -323.9 94.8 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 3 3 37 Lock Lock Lock
Basic m Lock Lock Lock Lock 3 3 37 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 5 3 1 Lock Lock Lock
     Growth % Lock Lock Lock Lock 57.9 -28.4 -73.7 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 14 16 17 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 2 1 -1 Lock Lock Lock
     Growth % Lock Lock Lock Lock 112.1 -55.3 -256.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock 33.0 20.6 -122.3 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 67 79 222 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -12 -15 -17 Lock Lock Lock
     Growth % Lock Lock Lock Lock -29.7 -17.9 -14.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -264.1 -435.2 -1,897.4 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -13 -15 -18 Lock Lock Lock
     Growth % Lock Lock Lock Lock -25.5 -20.1 -17.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock -272.7 -457.4 -2,042.6 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -21 -21 -18 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -20 -21 -18 Lock Lock Lock
     Growth % Lock Lock Lock Lock -28.2 -2.3 15.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -430.0 -614.7 -1,967.3 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -12 -12 -15 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 3 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -1 1 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 10 10 15 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -15 -12 -15 Lock Lock Lock
     Growth % Lock Lock Lock Lock 3.0 18.0 -21.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -3.1 -3.6 -16.6 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 2 0 1 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 19 10 11 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 2 0 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock 2 10 9 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 13 18 17 Lock Lock Lock
Equity $m Lock Lock Lock Lock 6 -7 -5 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 8 -7 -4 Lock Lock Lock
     Growth % Lock Lock Lock Lock -49.9 -189.8 38.3 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -109.6 -208.6 -162.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -348.6 281.3 340.2 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -87.9 -275.3 -647.5 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -173.8 -5,246.4 0.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -103.8 -3,019.6 0.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -59.5 -57.3 -35.0 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock -0.2 -0.6 -0.5 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock 42.2 -128.5 -175.1 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 0.8 0.2 0.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 0.6 0.1 0.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 29.2 9.5 25.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -157.8 -89.9 -120.4 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 2.2 2.7 1.8 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 2.3 1.7 1.8 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 53.3 64.5 107.4 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.3 0.3 0.1 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.3 0.3 0.1 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -438.9 -623.8 -1,969.3 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -111.9 -211.7 -162.7 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -109.6 -208.6 -162.5 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 3.2 -1.3 -2.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -348.6 281.3 340.2 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -348.6 281.3 340.2 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 156.0 217.2 206.1 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 165.3 133.0 206.4 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 321.3 350.2 412.5 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 165.3 388.3 383.9 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 156.0 -38.1 28.6 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

RGT Shortsell

Frequently Asked Questions

The current share price of Argent Biopharma Ltd (RGT:ASX) is AU$0.08.
The 52-week high share price for Argent Biopharma Ltd (RGT:ASX) is AU$0.57.
The 52-week low share price for Argent Biopharma Ltd (RGT:ASX)? is AU$0.07.
Argent Biopharma Ltd (RGT:ASX) does not pay a dividend.
Argent Biopharma Ltd (RGT:ASX) does not pay a dividend.
Argent Biopharma Ltd (RGT:ASX) has a franking level of 0.0%.
Argent Biopharma Ltd (RGT:ASX) is classified in the Healthcare.
The current P/E ratio for Argent Biopharma Ltd (RGT:ASX) is .
The current share price of Argent Biopharma Ltd (RGT:ASX) is AU$0.08.
The 52-week high share price for Argent Biopharma Ltd (RGT:ASX) is AU$0.57.
The 52-week low share price for Argent Biopharma Ltd (RGT:ASX)? is AU$0.07.
Argent Biopharma Ltd (RGT:ASX) does not pay a dividend.
Argent Biopharma Ltd (RGT:ASX) does not pay a dividend.
Argent Biopharma Ltd (RGT:ASX) has a franking level of 0.0%.
Argent Biopharma Ltd (RGT:ASX) is classified in the Healthcare.
The current P/E ratio for Argent Biopharma Ltd (RGT:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.